Lilly Scores Twice, Boehringer Ingelheim Once At EMA
This article was originally published in The Pink Sheet Daily
Executive Summary
Boehringer Ingelheim’s Vargatef and Eli Lilly’s Cyramza, both cancer drugs, got the nod from EMA this month, while Lilly also received a thumbs-up for its Trulicity diabetes therapy.
You may also be interested in...
Gilead Gets Positive EU Opinion On Proprietary HCV Combo Pill Harvoni
Europe’s top scientific advisory panel has cleared for approval Gilead’s new hepatitis C antiviral combination of sofosbuvir plus ledipasvir, as well as Almirall’s new inhaled combo of aclidinium and formoterol and AstraZeneca’s new constipation therapy naloxegol.
Lilly Prices Trulicity Near Victoza, But Well Above Tanzeum
Easy-to-use pen with invisible needle to deliver Lilly’s GLP-1 agonist dulaglutide is an asset compared to delivery of other once-weeklies in the class, but the crowded market is still very challenging.
MHRA’s Beneficial EU Relationship And Profitable Synergies With NICE: An Interview With Michael Rawlins
In December, Michael Rawlins was appointed head of the U.K.’s Medicines and Healthcare products Regulatory Agency. He recognizes the MHRA’s mutually beneficial relationship with European counterparts and is looking to safeguard synergies with other national regulatory bodies and NICE.